Liraglutide (Victoza)

Peptide

Approvedregulatory verdict

Evidence outlook

Approved: Type 2 Diabetes, Atherosclerotic Cardiovascular Disease

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (2)
JP
  • Victoza: type 2 diabetes
Product first approved 2010novonordisk.com
EU
  • Victoza: type 2 diabetes mellitus (adults, adolescents and children from 10 years)
Product first approved 2009EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (69)
Atherosclerotic Cardiovascular Disease
NCT05467514 · David Sanchez Garcia
2022-07-01 – 2023-02-28 · Diabetes Mellitus, Type 1
What this study did
Type 2 Diabetes
NCT06559722 · Tonghua Dongbao Pharmaceutical Co.,Ltd
2024-08 – 2026-02 · Type 2 Diabetes
What this study did
NCT05767255 · Hospital Universitario San Ignacio
2022-12-01 – 2023-08-30 · Diabetes Mellitus, Type 2 Treated With Insulin
What this study did
NCT04057261 · RWTH Aachen University
2020-11 – 2022-11 · Type 2 Diabetes, Cardiovascular Diseases
What this study did
NCT05360147 · Third Military Medical University
2021-01-20 – 2021-05-10 · Type 2 Diabetes Mellitus
What this study did
NCT01794143 · GRADE Study Group
2013-05 – 2021-04-30 · Type 2 Diabetes, Comparative Effectiveness of Glycemia-lowering Medications
What this study did
NCT02889510 · Lecube, Albert, M.D.
2016-10-04 – 2019-12-16 · Type 2 Diabetes
What this study did
NCT03421119 · Cinnagen
2019-06-20 – 2019-12-01 · Diabetes Mellitus, Type 2
What this study did
NCT01779362 · RISE Study Group
2013-04 – 2019-08 · Prediabetes, Type 2 Diabetes
What this study did
NCT03172494 · Novo Nordisk A/S
2017-05-26 – 2019-07-13 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01234649 · Woman's
2011-08-11 – 2019-06-14 · Gestational Diabetes Mellitus, Type 2 Diabetes Mellitus, Metabolic Syndrome, Impaired Glucose Tolerance, Disorder of Glucose Regulation
What this study did
NCT03707171 · Third Military Medical University
2018-10-01 – 2019-05-01 · Type 2 Diabetes Mellitus
What this study did
NCT02501161 · Novo Nordisk A/S
2016-01-31 – 2018-10-03 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT02964247 · Novo Nordisk A/S
2017-03-03 – 2018-05-08 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT02607306 · Novo Nordisk A/S
2015-11-18 – 2017-12-22 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT02505334 · Novo Nordisk A/S
2015-07-21 – 2017-11-09 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT02638805 · Intarcia Therapeutics
2015-12 – 2017-10 · Diabetes Mellitus, Type 2
What this study did
NCT02043054 · University of Leicester
2013-12-16 – 2017-09-29 · Type 2 Diabetes Mellitus, Cardiovascular Disease
What this study did
NCT02718950 · University of Campinas, Brazil
2016-06 – 2017-04 · Obesity, Type 2 Diabetes Mellitus
What this study did
NCT02420262 · Novo Nordisk A/S
2015-07-26 – 2016-10-05 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT02298192 · Novo Nordisk A/S
2014-11-21 – 2015-12-23 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01628445 · University of Manitoba
2012-08 – 2015-11 · Type 2 Diabetes
What this study did
NCT01937598 · Michael A. Nauck
2013-08 – 2015-06 · Type 2 Diabetes
What this study did
NCT01952145 · Novo Nordisk A/S
2013-09-20 – 2014-11-04 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01270789 · Mount Sinai Hospital, Canada
2011-01 – 2014-05 · Type 2 Diabetes
What this study did
NCT01676116 · Novo Nordisk A/S
2012-08-29 – 2014-03-11 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01664247 · Novo Nordisk A/S
2012-10-01 – 2013-12-31 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01617434 · Novo Nordisk A/S
2012-09 – 2013-10 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01620489 · Novo Nordisk A/S
2012-06-14 – 2013-08-20 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01512108 · Novo Nordisk A/S
2012-01-10 – 2013-04-26 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01572740 · Novo Nordisk A/S
2012-04-05 – 2013-03-27 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01392573 · Novo Nordisk A/S
2011-11-28 – 2012-10-04 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01388361 · Novo Nordisk A/S
2011-09 – 2012-07 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00856986 · Novo Nordisk A/S
2009-03 – 2010-11 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00700817 · Novo Nordisk A/S
2008-06 – 2010-06 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00620282 · Novo Nordisk A/S
2008-02 – 2010-05 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00518882 · Novo Nordisk A/S
2007-08 – 2009-04 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00614120 · Novo Nordisk A/S
2008-01 – 2009-02 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00294723 · Novo Nordisk A/S
2006-02 – 2008-11 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00393718 · Novo Nordisk A/S
2006-11 – 2008-05 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00395746 · Novo Nordisk A/S
2006-10 – 2008-05 · Diabetes, Diabetes Mellitus, Type 2
What this study did
Phase 2/3 (5)
Other / comorbidity
NCT01879917 · Hvidovre University Hospital
2014-02 – 2018-08 · Diabetes Mellitus, Type 1
What this study did
NCT02351232 · Hvidovre University Hospital
2015-02 – 2016-10 · Type 1 Diabetes
What this study did
NCT02584582 · Hvidovre University Hospital
2015-07 – 2015-11 · Type 1 Diabetes
What this study did
NCT01610934 · University Hospital, Gentofte, Copenhagen
2012-08 – 2013-08 · Maturity-onset Diabetes of the Young
What this study did
NCT00993720 · Hvidovre University Hospital
2009-10 – 2010-10 · Diabetes Mellitus
What this study did
Phase 2 (37)
Atherosclerotic Cardiovascular Disease
NCT02315001 · King's College London
2014-01 – 2015-03 · Ischaemic Heart Disease, Coronary Heart Disease, Chronic Stable Angina
What this study did
Type 2 Diabetes
NCT06976619 · Mayo Clinic
2025-10-03 – 2029-03-31 · Type 1 Diabetes, Type 2 Diabetes
What this study did
NCT04535960 · University Health Network, Toronto
2019-03-14 – 2021-03-16 · Type 2 Diabetes Mellitus
What this study did
NCT03426085 · Eastern Virginia Medical School
2016-05 – 2020-08 · Autonomic Nervous System Diseases, Sweat Gland Diseases, Diabetic Neuropathy With Neurologic Complication
What this study did
NCT02472717 · University Health Network, Toronto
2015-05 – 2016-10 · Psoriatic Arthritis, Psoriasis, Impaired Glucose Tolerance, Type 2 Diabetes
What this study did
NCT01425580 · Thomas Nystrom
2012-01 – 2016-08 · Congestive Heart Failure, Type 2 Diabetes Mellitus
What this study did
NCT02113332 · Vastra Gotaland Region
2013-01 – 2014-08 · Type 2 Diabetes Mellitus
What this study did
NCT01399645 · Centre hospitalier de l'Université de Montréal (CHUM)
2011-05 – 2014-06 · Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Type 2 Diabetes
What this study did
NCT01725126 · GlaxoSmithKline
2013-02-10 – 2013-09-12 · Obesity
What this study did
NCT01516476 · Hoffmann-La Roche
2011-11 – 2012-01 · Diabetes Mellitus Type 2
What this study did
NCT00696657 · Novo Nordisk A/S
2008-06-03 – 2009-02-05 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00154414 · Novo Nordisk A/S
2005-01 – 2006-05 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00154401 · Novo Nordisk A/S
2005-01 – 2005-10 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01508949 · Novo Nordisk A/S
2001-06 – 2002-03 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01508923 · Novo Nordisk A/S
2001-05 – 2002-02 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01511198 · Novo Nordisk A/S
2001-02 – 2001-10 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01509755 · Novo Nordisk A/S
2000-10 – 2001-10 · Diabetes, Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT07029009 · Mansa
2025-05-08 – 2027-01 · Maturity Onset Diabetes of the Young
What this study did
NCT02611232 · University of Oulu
2015-12 – 2024-06 · Type 1 Diabetes
What this study did
NCT04763564 · University of North Carolina, Chapel Hill
2022-03-22 – 2023-10-16 · Pouchitis, Irritable Pouch Syndrome
What this study did
NCT02953665 · Cedars-Sinai Medical Center
2017-04-03 – 2022-08-03 · Parkinson Disease
What this study did
NCT03712098 · Rebecca Ashare
2018-11-29 – 2022-05-25 · Smoking Cessation, Weight, Body
What this study did
NCT02898506 · University of Oulu
2016-03 – 2021-06 · Type 1 Diabetes
What this study did
NCT02908087 · University of Oulu
2016-03 – 2021-05 · Type 1 Diabetes
What this study did
NCT03371862 · Imperial College London
2017-10-20 – 2020-09-30 · Short Bowel Syndrome
What this study did
NCT02617654 · Per-Ola Carlsson
2015-11 – 2020-09 · Type 1 Diabetes
What this study did
NCT01843075 · Imperial College London
2014-01 – 2019-12 · Alzheimer's Disease
What this study did
NCT01845259 · Psychiatric Centre Rigshospitalet
2013-04 – 2017-03 · Impaired Glucose Tolerance Associated With Drugs
What this study did
NCT02408705 · Medical University of Graz
2015-01 – 2016-05 · Type 1 Diabetes Mellitus
What this study did
NCT01800968 · Duke University
2013-04 – 2015-10 · Acute Heart Failure
What this study did
NCT02284230 · Bo Feldt-Rasmussen
2014-12 – 2015-08 · Kidney Failure, Chronic, Prediabetic State
What this study did
NCT01782261 · Medical University of Graz
2012-02 – 2015-02 · Type 1 Diabetes
What this study did
NCT01755416 · Albert Einstein College of Medicine
2013-01 – 2015-01 · Type 1 Diabetes
What this study did
NCT01237119 · University of Birmingham
2010-08 – 2014-07 · Nonalcoholic Steatohepatitis
What this study did
NCT01206101 · Novo Nordisk A/S
2012-03-21 – 2013-06-03 · Diabetes, Diabetes Mellitus, Type 1
What this study did
Phase 1/2 (6)
Type 2 Diabetes
NCT05268237 · Biolingus
2023-04-25 – 2026-03 · Diabete Type 2
What this study did
NCT02960659 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
2017-05-09 – 2022-05-20 · Type 2 Diabetes
What this study did
NCT01954147 · Diabetes Care Center of Nanjing Military Command
2013-10 – 2015-10 · Type 2 Diabetes
What this study did
Other / comorbidity
NCT03011021 · Second Xiangya Hospital of Central South University
2017-01 – 2025-06 · Type1 Diabetes Mellitus, Autoimmune Diabetes
What this study did
NCT03182426 · University of Alberta
2017-08-15 – 2024-07-15 · Diabetes Mellitus, Type 1
What this study did
NCT04199728 · Milton S. Hershey Medical Center
2021-10-18 – 2023-09-13 · Opiate Substitution Treatment, Opioid-Related Disorders
What this study did
Phase 1 (50)
Type 2 Diabetes
NCT06439056 · Nanexa AB
2024-05-27 – 2025-07-18 · Type 2 Diabetes
What this study did
NCT05294536 · Sunshine Lake Pharma Co., Ltd.
2020-06-22 – 2020-11-27 · Type 2 Diabetes
What this study did
NCT02650206 · Stanford University
2015-01 – 2019-09-27 · Diabetes Mellitus, Type 2, Diabetes Mellitus, Type II, Diabetes Mellitus, Adult-Onset, Inflammation
What this study did
NCT05029076 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2019-05-21 – 2019-07-01 · Type 2 Diabetes
What this study did
NCT03292185 · Novo Nordisk A/S
2017-09-29 – 2018-01-02 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT02059564 · Hanmi Pharmaceutical Company Limited
2013-12 – 2014-12 · Diabetes Mellitus
What this study did
NCT01870297 · Eli Lilly and Company
2013-06 – 2014-12 · Type 2 Diabetes Mellitus
What this study did
NCT01916174 · Novo Nordisk A/S
2013-08 – 2013-11 · Diabetes, Diabetes Mellitus, Type 2, Healthy
What this study did
NCT01473953 · Novo Nordisk A/S
2011-10 – 2012-03 · Diabetes, Diabetes Mellitus, Type 2, Healthy
What this study did
NCT00943501 · Novo Nordisk A/S
2009-11 – 2011-09 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01373450 · Merck Sharp & Dohme LLC
2011-06 – 2011-07 · Type 2 Diabetes Mellitus
What this study did
NCT00993304 · Novo Nordisk A/S
2009-10 – 2010-12 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00873223 · Novo Nordisk A/S
2009-03 – 2009-09 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01511692 · Novo Nordisk A/S
2005-11 – 2007-09 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01517555 · Novo Nordisk A/S
2006-10 – 2007-05 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01508858 · Novo Nordisk A/S
2006-11 – 2007-04 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01516255 · Novo Nordisk A/S
2006-07 – 2006-11 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01507389 · Novo Nordisk A/S
2006-03 – 2006-06 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01515592 · Novo Nordisk A/S
2006-01 – 2006-04 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01508806 · Novo Nordisk A/S
2005-08 – 2006-03 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01615978 · Novo Nordisk A/S
2003-12 – 2004-03 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01620463 · Novo Nordisk A/S
2002-12 – 2003-03 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01509742 · Novo Nordisk A/S
2001-04 – 2001-11 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01511185 · Novo Nordisk A/S
2001-02 – 2001-10 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01507311 · Novo Nordisk A/S
1999-09 – 1999-12 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01507285 · Novo Nordisk A/S
1999-08 – 1999-11 · Diabetes, Diabetes Mellitus, Type 2, Healthy
What this study did
Other / comorbidity
NCT06449703 · Tonghua Dongbao Pharmaceutical Co.,Ltd
2024-05-06 – 2024-06-16 · Healthy
What this study did
NCT05444569 · Eli Lilly and Company
2022-08-08 – 2023-02-24 · Healthy
What this study did
NCT03632759 · Carla Greenbaum, MD
2018-08-15 – 2021-11-09 · Type 1 Diabetes Mellitus
What this study did
NCT02231658 · Profil Institut für Stoffwechselforschung GmbH
2015-07-16 – 2018-07-23 · Diabetes Mellitus
What this study did
NCT02140983 · Stanford University
2013-08 – 2017-02 · Insulin Resistance, Dementia
What this study did
NCT01856790 · Jennifer Sherr
2013-02 – 2015-11 · Type 1 Diabetes
What this study did
NCT02109315 · Anna Cruceta
2014-05 – 2015-05 · Type 1 Diabetes Mellitus
What this study did
NCT01550653 · University of Luebeck
2012-05 – 2013-12 · Healthy
What this study did
NCT01536665 · Novo Nordisk A/S
2012-02 – 2012-08 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01319240 · Novo Nordisk A/S
2011-03 – 2011-05 · Diabetes, Healthy
What this study did
NCT00983021 · Novo Nordisk A/S
2009-09 – 2009-12 · Diabetes, Healthy
What this study did
NCT01513525 · Novo Nordisk A/S
2007-02 – 2007-05 · Diabetes, Healthy
What this study did
NCT01515553 · Novo Nordisk A/S
2007-01 – 2007-04 · Diabetes, Healthy
What this study did
NCT01518166 · Novo Nordisk A/S
2006-05 – 2007-04 · Diabetes, Healthy
What this study did
NCT01517568 · Novo Nordisk A/S
2006-11 – 2006-12 · Diabetes, Healthy
What this study did
NCT01515579 · Novo Nordisk A/S
2006-04 – 2006-06 · Diabetes, Healthy
What this study did
NCT01514487 · Novo Nordisk A/S
2005-01-13 – 2005-03-30 · Diabetes, Healthy
What this study did
NCT01508897 · Novo Nordisk A/S
2004-05-28 – 2004-06-30 · Diabetes, Healthy
What this study did
NCT01507337 · Novo Nordisk A/S
2004-04 – 2004-06 · Diabetes, Healthy
What this study did
NCT01620476 · Novo Nordisk A/S
2003-09 – 2004-03 · Diabetes, Healthy
What this study did
NCT01511159 · Novo Nordisk A/S
2001-10 – 2001-12 · Diabetes, Healthy
What this study did
NCT01507272 · Novo Nordisk A/S
1999-03 – 1999-12 · Diabetes, Healthy
What this study did
Phase 4 (78)
Atherosclerotic Cardiovascular Disease
NCT03260881 · University of Miami
2018-09-01 – 2024-09-05 · Type2 Diabetes, Coronary Artery Disease
What this study did
NCT04881110 · University of Campania Luigi Vanvitelli
2021-02-01 – 2022-12-31 · Type 2 Diabetes, Peripheral Arterial Disease
What this study did
NCT01595789 · Haugaard, Steen Bendix, M.D., DMSc
2012-05 – 2015-07 · Coronary Artery Disease, Diabetes Mellitus, Type 2
What this study did
Type 2 Diabetes
NCT07244003 · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
2025-03-29 – 2028-06-30 · T2DM (Type 2 Diabetes Mellitus)
What this study did
NCT03883412 · University of Virginia
2019-02-28 – 2027-12 · Type2 Diabetes
What this study did
NCT06408532 · Peking University People's Hospital
2024-04-30 – 2025-02-28 · Diabetes Mellitus, Type 2
What this study did
NCT03087032 · The First Affiliated Hospital of Xiamen University
2019-01-10 – 2025-02-10 · Type 2 Diabetes Patients, Overweight and Obesity, Hyperglycaemia (Diabetic)
What this study did
NCT02344186 · Temple University
2014-05 – 2023-12-31 · Type 2 Diabetes
What this study did
NCT04657939 · University of Leeds
2020-12-01 – 2022-10-31 · Diabetes Mellitus, Type 2
What this study did
NCT05360537 · University of Palermo
2021-04-01 – 2022-04-20 · Diabetes Mellitus, Type 2
What this study did
NCT04146155 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2020-05-01 – 2021-12-31 · Type 2 Diabetes, Peripheral Vascular Disorder Due to Diabetes Mellitus
What this study did
NCT02686177 · Assistance Publique - Hôpitaux de Paris
2016-05-18 – 2021-05-28 · Type 2 Diabetes
What this study did
NCT02198209 · Cedars-Sinai Medical Center
2019-12 – 2020-12 · Type 2 Diabetes
What this study did
NCT01795248 · Tina Vilsboll
2012-07 – 2020-09 · Gestational Diabetes Mellitus
What this study did
NCT01919489 · Emory University
2014-03 – 2020-08-30 · Type 2 Diabetes
What this study did
NCT02535299 · Third Military Medical University
2016-06 – 2019-12 · GLP-1;Metformin;Telomere-telomerase System;Par-4
What this study did
NCT02655770 · Copenhagen University Hospital, Rigshospitalet
2016-02 – 2019-12 · Diabetes Mellitus Type 2, Diastolic Dysfunction, Cardiac MRI, Myocardial Perfusion
What this study did
NCT02721888 · Centre Hospitalier Universitaire Dijon
2012-07-10 – 2019-10-02 · Type 2 Diabetes
What this study did
NCT03449654 · Steno Diabetes Center Copenhagen
2017-10-26 – 2019-08-16 · Diabetes Mellitus, Type 2
What this study did
NCT02765399 · Helsinki University Central Hospital
2015-02-01 – 2019-02-28 · Type 2 Diabetes
What this study did
NCT02743598 · Temple University
2016-09 – 2018-09 · HIV Infection, Diabetes Mellitus Type 2, Obesity, Overweight, Metabolic Syndrome
What this study did
NCT02660047 · Leiden University Medical Center
2015-08 – 2018-03-09 · Diabetes Mellitus Type 2, Metabolic Syndrome, Cardiovascular Disease, Diastolic Dysfunction, Fatty Liver
What this study did
NCT01966978 · University of Texas Southwestern Medical Center
2014-11 – 2017-12 · Diabetes Mellitus, Type 2, Diabetes
What this study did
NCT02147925 · Sun Yat-sen University
2014-08 – 2017-04 · Non-alcoholic Fatty Liver Disease
What this study did
NCT02055014 · Sandwell & West Birmingham Hospitals NHS Trust
2013-07 – 2017-03 · Type 2 Diabetes, Obesity, Diabesity
What this study did
NCT02014740 · University of Miami
2014-03 – 2017-03 · Type 2 Diabetes, Overweight, Obesity
What this study did
NCT02832999 · Yaounde Central Hospital
2016-01 – 2016-12 · Type 2 Diabetes Mellitus
What this study did
NCT02299388 · Tulane University School of Medicine
2014-10 – 2016-12 · Diabetes Mellitus, Non-Insulin-Dependent, Hypertensive Disease
What this study did
NCT02503943 · Third Affiliated Hospital of Third Military Medical University
2015-05 – 2016-09 · Type 2 Diabetes, Overweight, Obesity, Masked Hypertension
What this study did
NCT02674893 · Centre Hospitalier Universitaire Dijon
2014-02-04 – 2016-08-31 · Type 2 Diabetes, Overweight
What this study did
NCT01505673 · Ildiko Lingvay
2012-01 – 2016-06 · Type 2 Diabetes Mellitus, Obesity
What this study did
NCT01761318 · Leiden University Medical Center
2013-11 – 2016-03 · Diabetes Mellitus Type 2, Metabolic Syndrome, Cardiovascular Disease, Diastolic Dysfunction, Fatty Liver
What this study did
NCT01790308 · Sun Yat-sen University
2013-02 – 2015-12 · Diabetes Mellitus, Type 2
What this study did
NCT02072096 · Eli Lilly and Company
2014-02 – 2015-10 · Diabetes Mellitus, Type 2
What this study did
NCT02501850 · Hospital Universitari Vall d'Hebron Research Institute
2014-10 – 2015-10 · Diabetes Mellitus Type 2
What this study did
NCT03068065 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
2014-05 – 2015-10 · Non-Alcoholic Fatty Liver Disease, Type2 Diabetes
What this study did
NCT01744236 · Amsterdam UMC, location VUmc
2013-04 – 2015-08 · Type 2 Diabetes
What this study did
NCT01907854 · Novo Nordisk A/S
2013-12-02 – 2015-06-15 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01973231 · Novo Nordisk A/S
2013-10 – 2014-11 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT02008682 · Novo Nordisk A/S
2013-12 – 2014-11 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01917656 · Novo Nordisk A/S
2014-01-09 – 2014-09-04 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01785043 · Anna Cruceta
2013-03 – 2014-09 · DIABETES Mellitus Type 2 Not Well Controlled
What this study did
NCT01499108 · Peter Rossing
2012-08 – 2014-08 · Type 2 Diabetes
What this study did
NCT01597531 · East Carolina University
2012-06 – 2014-06 · Type 2 Diabetes, Gastric Banding
What this study did
NCT01455441 · Tina Vilsboll
2011-10 – 2014-06 · Type 2 Diabetes
What this study did
NCT01931982 · Bispebjerg Hospital
2013-05 – 2014-04 · Type 2 Diabetes, Microvascular Dysfunction
What this study did
NCT01755572 · Mount Sinai Hospital, Canada
2013-01 – 2014-03 · Type 2 Diabetes, Systolic Hypertension
What this study did
NCT01664676 · University of Aarhus
2012-12 – 2014-02 · Type 2 Diabetes Mellitus
What this study did
Early phase / not applicable (31)
Atherosclerotic Cardiovascular Disease
Type 2 Diabetes
NCT02879409 · Weill Cornell Medical College in Qatar
2016-11 – 2026-10-01 · Diabetes Mellitus Type 2
What this study did
NCT05313529 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
2022-10-08 – 2026-07-01 · Type 2 Diabetes Mellitus, Mild Cognitive Impairment
What this study did
NCT04324229 · Turku University Hospital
2020-02-07 – 2025-04-09 · Gestational Diabetes
What this study did
NCT03948347 · First Affiliated Hospital of Jinan University
2019-06-25 – 2024-06 · Ischemic Stroke, Transient Ischemic Attack, Type 2 Diabetes Mellitus
What this study did
NCT04829903 · Corporacion Parc Tauli
2020-01-02 – 2021-11-20 · Type 2 Diabetes Treated With Insulin, Obesity, Adolescent Obesity
What this study did
NCT04190160 · Stefano Rizza
2018-11-19 – 2021-03-25 · Type2 Diabetes
What this study did
NCT02324842 · The University of Texas Health Science Center at San Antonio
2014-11 – 2019-03-31 · Type 2 Diabetes Mellitus
What this study did
NCT01232946 · Indiana University
2012-01 – 2017-09-08 · Type 2 Diabetes
What this study did
NCT02783196 · Tel Aviv University
2016-07 – 2017-06 · Type 2 Diabetes
What this study did
NCT02036372 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
2014-01 – 2017-01 · Diabetes Mellitus Type II
What this study did
NCT01740921 · Royal Devon and Exeter NHS Foundation Trust
2011-01 – 2016-02 · Type 2 Diabetes
What this study did
NCT01472640 · Flyvbjerg, Allan, DMSc
2011-11 – 2015-10 · Hyperglycemia, Chronic Heart Failure
What this study did
NCT01363609 · Amsterdam UMC, location VUmc
2011-10 – 2015-01 · Obesity, Type 2 Diabetes
What this study did
NCT01392898 · Radboud University Medical Center
2012-02 – 2014-05 · Type 2 Diabetes Mellitus
What this study did
NCT01599338 · Centre Hospitalier Universitaire Dijon
2011-01 – 2011-09 · Type 2 Diabetes Mellitus, Overweight
What this study did
Other / comorbidity
NCT06818292 · Nils Opel
2024-10-21 – 2024-12-06 · Healthy
What this study did
NCT06500130 · Alimetry
2024-05-30 – 2024-11-30 · Gastroparesis, Functional Dyspepsia, Chronic Nausea and Vomiting Syndrome, Healthy
What this study did
NCT05390307 · Dasman Diabetes Institute
2023-04-01 – 2024-01-01 · Type 1 Diabetes
What this study did
NCT04137328 · Fudan University
2019-11-30 – 2022-11-30 · Diabetic Neuropathic Pain
What this study did
NCT02930265 · Chinese PLA General Hospital
2016-09 – 2018-03 · Ischemic Cardiomyopathy
What this study did
NCT02138045 · Aalborg University Hospital
2014-05 – 2017-02 · Diabetes Mellitus, Type 1, Type 1 Diabetes Mellitus
What this study did
NCT02777073 · University at Buffalo
2016-03-01 – 2016-12-31 · Type 1 Diabetes
What this study did
NCT02507128 · Chen Wei Ren, MD
2015-07 – 2016-07 · Acute ST-segment Elevation Myocardial Infarction
What this study did
NCT02490176 · Chinese PLA General Hospital
2015-07 – 2016-07 · Heart Failure
What this study did
NCT02001363 · Chen Wei Ren, MD
2013-11 – 2016-03 · Acute Myocardial Infarction
What this study did
NCT01575301 · University of Dundee
2011-03 – 2015-12-11 · Diabetes
What this study did
NCT02104037 · Mikkel Christensen
2012-01 – 2013-12 · Liraglutide Blood-brain Transfer
What this study did
NCT01460069 · Annesofie Faurschou
2011-10 – 2013-05 · Psoriasis
What this study did
NCT01469351 · University of Aarhus
2012-01 – 2013-04 · Alzheimers Disease
What this study did
NCT01451905 · University Hospital, Gentofte, Copenhagen
2011-08 – 2012-12 · Reduction of Psoriasis Following Liraglutide Therapy in Terms of PASI and DLQI
What this study did
Used as active comparator (26)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (11)
Type 2 Diabetes
NCT04373967 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2020-04-29 – 2021-12-02 · Type 2 Diabetes
What this study did
NCT03018028 · Novo Nordisk A/S
2017-01-10 – 2018-08-15 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT03191396 · Novo Nordisk A/S
2017-06-27 – 2018-08-13 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT02863419 · Novo Nordisk A/S
2016-08-10 – 2018-03-30 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01733758 · GlaxoSmithKline
2013-02 – 2015-02 · Diabetes Mellitus, Type 2
What this study did
NCT01558271 · Eli Lilly and Company
2012-03 – 2014-05 · Type 2 Diabetes Mellitus
What this study did
NCT01624259 · Eli Lilly and Company
2012-06 – 2013-11 · Type 2 Diabetes
What this study did
NCT01296412 · Merck Sharp & Dohme LLC
2011-03-11 – 2012-02-29 · Diabetes Mellitus, Type 2
What this study did
NCT01128894 · GlaxoSmithKline
2010-05 – 2011-09 · Diabetes Mellitus, Type 2
What this study did
NCT01029886 · AstraZeneca
2010-01 – 2011-04 · Type 2 Diabetes Mellitus
What this study did
Phase 2 (10)
Type 2 Diabetes
NCT03555994 · MedImmune LLC
2018-05-31 – 2021-04-14 · Type 2 Diabetes Mellitus
What this study did
NCT03235050 · AstraZeneca
2017-08-02 – 2019-06-14 · Diabetes Mellitus, Type 2
What this study did
NCT02973321 · Sanofi
2016-12-02 – 2017-12-27 · Type 2 Diabetes Mellitus
What this study did
NCT02492763 · Merck Sharp & Dohme LLC
2015-07-27 – 2017-04-18 · Type II Diabetes Mellitus
What this study did
NCT02461589 · Novo Nordisk A/S
2015-09-21 – 2016-10-13 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT02205528 · Novo Nordisk A/S
2014-08-18 – 2015-09-15 · Diabetes, Diabetes Mellitus Type 2
What this study did
NCT02057172 · Hanmi Pharmaceutical Company Limited
2014-01 – 2014-12 · Type 2 Diabetes
What this study did
NCT01175473 · Sanofi
2010-08 – 2010-11 · Type 2 Diabetes Mellitus
What this study did
Other / comorbidity
Phase 1 (4)
Type 2 Diabetes
NCT03115099 · Eli Lilly and Company
2017-05-31 – 2018-04-05 · Diabetes Mellitus, Type 2
What this study did
NCT01982630 · Merck Sharp & Dohme LLC
2013-11-07 – 2014-10-03 · Diabetes Mellitus
What this study did
Other / comorbidity
NCT05794581 · Carmot Therapeutics, Inc.
2023-03-21 – 2024-04-06 · Type 1 Diabetes
What this study did
NCT05225974 · The Affiliated Hospital of Qingdao University
2021-07-16 – 2021-08-19 · Therapeutic Equivalency
What this study did
Phase 4 (1)
Type 2 Diabetes
NCT01117350 · Sanofi
2010-07 – 2013-03 · Diabetes Mellitus, Type 2
What this study did

Competitive landscape

This mechanism is crowded: 50 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Atherosclerotic Cardiovascular Disease: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Liraglutide (Victoza): this drugApprovedPeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Alirocumab (Praluent)ApprovedMonoclonal antibodyPCSK9Weak signal
NCT03510884: DB Period: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 24: Intent-to-treat (ITT) Estimand (Baseline, Week 24): DB Period: Alirocumab Q2W -33.6 percent change (Standard Error 3.4) | Db Period: Alirocumab Q4W -38.2 percent change (Standard Error 4) vs DB Period: Placebo Q2W 9.7 percent change (Standard Error 4.3) | Db Period: Placebo Q4W -4.4 percent change (Standard Error 3.7)
NCT01709500: Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent--to--Treat (ITT) Analysis (From Baseline to Week 52): Alirocumab 75 mg/up to 150 mg -48.7 percent change (Standard Error 1.9) vs Placebo 2.8 percent change (Standard Error 2.8)
Bempedoic Acid (Nexletol)ApprovedSmall moleculeATP citrate lyasePartial signal
NCT02991118: Percent Change From Baseline to Week 12 in Low-density Lipoprotein Cholesterol (LDL-C) (Baseline; Week 12): Bempedoic Acid -15.07 percent change (Standard Error 1.073) vs Placebo 2.35 percent change (Standard Error 1.446)
NCT02988115: Percent Change From Baseline (PCFB) in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12 (Baseline; Week 12): Bempedoic Acid -22.58% (Standard Error 1.29) vs Placebo -1.17% (Standard Error 1.421)
Bempedoic Acid / Ezetimibe (Nexlizet)ApprovedSmall moleculeATP citrate lyase (ACLY, bempedoic acid) and NPC1L1 (ezetimibe)Partial signal
NCT03337308: Percent Change From Baseline to Week 12 in Low-density Lipoprotein Cholesterol (LDL-C) (Baseline; Week 12): Bempedoic Acid 180 mg + Ezetimibe 10 mg FDC -36.2% (Standard Error 2.56) vs Bempedoic Acid 180 mg -17.2% (Standard Error 2.52) vs Ezetimibe 10 mg -23.2% (Standard Error 2.18) vs Placebo 1.8% (Standard Error 3.49)
Cangrelor (Kengreal)ApprovedSmall moleculeP2Y12 receptorPartial signal
NCT00385138: Death, MI or ischemia-driven revascularization at 48 h: 7.0% cangrelor (185/2654) vs 8.0% placebo (210/2641); OR 0.87, 95% CI 0.71 to 1.07; P=0.17. Both arms received clopidogrel 600 mg (CHAMPION PLATFORM, NEJM 2009). missed
Colchicine (cardiovascular) (Lodoco)ApprovedSmall moleculeMicrotubule/inflammasome (tubulin)not yet gradedNo reviewed efficacy summary in this indication
Dulaglutide (Trulicity)ApprovedPeptideGLP-1 receptorReliable signal
NCT01394952: Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome) (From randomization to first occurrence or death from any cause or study completion (Median Follow-Up of 5.4 Years)): Dulaglutide 594/4949 vs Placebo 663/4952
Empagliflozin (Jardiance)ApprovedSmall moleculeSGLT2not yet gradedNo reviewed efficacy summary in this indication
Evolocumab (Repatha)ApprovedMonoclonal antibodyPCSK9Partial signal
NCT02392559: Percent Change From Baseline to Week 24 in LDL-C (Baseline, Week 24): EvoMab 420 mg QM -44.53 percent change (Standard Error 2.17) vs Placebo -6.23 percent change (Standard Error 3.08)
NCT02207634: Mean Change From Baseline in Spatial Working Memory Strategy Index of Executive Function (6-8 Boxes) Z Score (Assessments were conducted at Baseline and at weeks 24, 48, 96, 144 and end of study visit (median time on study was 19.4 months).): Evolocumab 0.1134 Z score (95% CI 0.0449 to 0.182) vs Placebo 0.1206 Z score (95% CI 0.0535 to 0.1877)
Ezetimibe / Simvastatin (Vytorin)ApprovedSmall moleculeHMG-CoA reductase / NPC1L1Reliable signal
NCT00202878: Time to First Occurrence of Cardiovascular Death, Major Coronary Event, or Non-fatal Stroke (Kaplan-Meier Estimate of Percentage of Participants Experiencing a Qualifying Event) (Up to approximately 9 years): Ezetimibe/Simvastatin 32.72% (95% CI 31.63 to 33.85) vs Simvastatin 34.67% (95% CI 33.56 to 35.81)
NCT00110435: Percent reduction in LDL-C from baseline at 6 weeks: ezetimibe/simvastatin 10/20mg -53.6% vs atorvastatin 10mg -38.3% (P<.001) and vs atorvastatin 20mg -44.6% (P<.001); ezetimibe/simvastatin 10/40mg -57.6% vs atorvastatin 40mg -50.9% (P<.001). Primary endpoint (percent change from baseline in LDL-C) significantly favored ezetimibe/simvastatin at both dose comparisons.
Icosapent Ethyl (Vascepa)ApprovedSmall moleculeOmega-3 fatty acid (EPA)Reliable signal
NCT01492361: Composite of CV Death, Nonfatal MI (Including Silent MI), Nonfatal Stroke, Coronary Revascularization, or Unstable Angina Determined to be Caused by Myocardial Ischemia by Invasive / Non-invasive Testing and Requiring Emergent Hospitalization. (Total follow-up time of up to approximately 6 years.): AMR101 705/4089 vs Placebo 901/4090
Liraglutide (Saxenda)
Approved(overall)
PeptideGLP-1 receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
RosuvastatinApprovedSmall moleculeHMG-CoA reductasenot yet gradedNo reviewed efficacy summary in this indication
Semaglutide (Ozempic)ApprovedPeptideGLP-1 receptorReliable signal
NCT04560998: Maximum walking distance at Week 52: semaglutide 1 mg superior to placebo by 13% (estimated treatment ratio 1.13; 95% CI 1.06-1.21; p=0.0004); median treatment difference 26.4 meters (~87 feet) on a 12% incline treadmill
NCT01720446: Time From Randomisation to First Occurrence of a MACE, Defined as Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (Time from randomisation up to end of follow-up (scheduled at week 109)): Semaglutide 6.6% vs Placebo 8.9%
Semaglutide (Rybelsus)ApprovedPeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Semaglutide (Wegovy Tablets)
Approved(overall)
PeptideGLP-1 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
Semaglutide (Wegovy)ApprovedPeptideGLP-1 receptorReliable signal
NCT03574597: Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke (From randomisation (week 0) up to 240 weeks): Semaglutide 569/8803 vs Placebo 701/8801
Ticagrelor (Brilinta)ApprovedSmall moleculeP2Y12 receptorPartial signalFeatured results are non-efficacy only in this race
Tirzepatide (Mounjaro)ApprovedPeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
AG2304Phase 3Small moleculeHMG-CoA reductase / NPC1L1Partial signalNo reviewed efficacy summary in this indication
AlprostadilPhase 3Small moleculeProstaglandin E1 receptornot yet graded
NCT01263925: ClinicalTrials.gov results section for NCT01263925 ('Intravenous Prostaglandin E1 Treatment in Outpatients With Intermittent Claudication', UCB Pharma, Phase 3, enrollment 561/541 FAS, completed April 2011 -- matches this record exactly). Primary outcome: pain-free walking-distance ratio vs active comparator (pentoxifylline) across three periods; both treatments produced similar improvements with no clear superiority of either. phase 3 result · pivotal pending
Amlodipine / Valsartan / Atorvastatin (CJ-30061)Phase 3Small moleculeAngiotensin II receptor / Calcium channel / HMG-CoA reductasePartial signalNo reviewed efficacy summary in this indication
Beperminogene Perplasmid (HGF Plasmid) (Collategene)Phase 3Gene therapy / editingHGF (hepatocyte growth factor), Hepatocyte growth factor (HGF)not yet gradedNo reviewed efficacy summary in this indication
Cilostazol / Rosuvastatin (UI022 / UI023)Phase 3Small moleculePDE3 (phosphodiesterase 3) and HMG-CoA reductaseReliable signal
NCT07600385: KPAQ summary score change (FAS, n=257): test group 15.41 points (SD 14.18) vs control group 10.27 points (SD 14.70); between-group difference 5.14 points (P=0.004), test group superior.
DalcetrapibPhase 3Small moleculeCETPPartial signal
NCT00658515: Primary composite cardiovascular endpoint, dalcetrapib vs placebo: hazard ratio 1.04 (95% CI 0.93 to 1.16), P=0.52; trial stopped for futility (NEJM 2012). missed
NCT01059682: Nominal Change From Baseline to Study End in Coronary Percent Atheroma Volume (PAV) of the Target Coronary Artery Assessed by IVUS. (24 months): Dalcetrapib 0.6% (Standard Deviation 3.69) vs Placebo 0.5% (Standard Deviation 2.01)
Dapagliflozin (Farxiga / Forxiga)Phase 3Small moleculeSGLT2not yet gradedNo reviewed efficacy summary in this indication
DWC202206 + DWC202207Phase 3Small molecule—Partial signalNo reviewed efficacy summary in this indication
EbronucimabPhase 3Monoclonal antibodyPCSK9Partial signal
NCT05255094: LDL-C percentage change from baseline to week 12 vs placebo: 450 mg Q4W -59.13 percentage points (95% CI -64.10 to -54.15, adjusted p<0.0001); 150 mg Q2W -60.43 percentage points (95% CI -65.45 to -55.416, adjusted p<0.0001).
Enlicitide (Lipfendra)Phase 3PeptidePCSK9Reliable signal
NCT05952856: Week 24 LDL-C mean percent change: -57.1% with enlicitide vs 3.0% with placebo; difference -55.8 percentage points (95% CI -60.9 to -50.7; p<0.001).
NCT05952869: Mean Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 24 (Baseline and Week 24): Enlicitide Decanoate -58.2% (Standard Deviation 28) vs Placebo 2.6% (Standard Deviation 23.6)
Ezetimibe (Zetia)Phase 3Small moleculeDietary Cholesterol Absorption Inhibitor, NPC1L1Reliable signal
NCT00092586: Percent change in LDL-C: ezetimibe+statin -25.8% vs placebo+statin -2.7%; treatment difference -23.1 percentage points (P<.001)
NCT03867318: Proportion achieving LDL-C goal <=100 mg/dL at Week 14: 22% (ezetimibe 10mg + atorvastatin, n=305) vs 7% (atorvastatin dose-titration alone, n=316); P<.01
Fimasartan / Atorvastatin / Ezetimibe (BR1017)Phase 3Small moleculeAT1 receptor; NPC1L1; HMG-CoA reductasePartial signal
NCT05930028: Week 8 co-primary endpoints (full analysis set, 148 randomized): mean sitting systolic BP, fimasartan + atorvastatin/ezetimibe vs atorvastatin/ezetimibe, LS mean difference -7.26 mm Hg (95% CI -12.91 to -1.61), P = 0.0124; LDL-C percent change, fimasartan + atorvastatin/ezetimibe vs fimasartan, LS mean difference -58.02% (95% CI -66.03 to -50.02), P < 0.0001 (Hong et al., Clin Ther 2025).
HyzetimibePhase 3Small moleculeNPC1L1Partial signal
NCT03433196: LDL-C percent change from baseline (primary endpoint, week 12): -16.39% (95% CI -19.04 to -13.74) with hyzetimibe (HS-25, referred to in this paper as hybutimibe) + atorvastatin vs -6.75% (95% CI -9.48 to -4.02) with atorvastatin alone, P<0.0001
NCT03413462: 第12周试验组LDL-C较基线的变化率为(-10.23±13.58)%,显著优于对照组(4.34±15.88)%。
Inclisiran (Leqvio)Phase 3RNA / oligonucleotidePCSK9Partial signal
NCT04652726: Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1) (Baseline and Day 330): Part 1- Inclisiran -27.14% (95% CI -32.04 to -22.24) vs Part 1 - Placebo 1.4% (95% CI -3.97 to 6.78)
NCT04659863: Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1) (Baseline and Day 330): Part 1- Inclisiran -21.6% (Standard Deviation 13.36) vs Part 1 - Placebo 11.7% (Standard Deviation 30.52)
LaroprovstatPhase 3Small moleculePCSK9Reliable signal
NCT06173570: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) Level From Baseline to Week 12 (From first day of treatment up to week 12): AZD0780 1 mg -31.19% (95% CI -37.06--25.32) vs AZD0780 3 mg -33.83% (95% CI -39.78--27.88) vs AZD0780 10 mg -41.09% (95% CI -46.92--35.25) vs AZD0780 30 mg -46.62% (95% CI -52.48--40.76) vs Placebo 4.08% (95% CI -1.84-10.00); p=< 0.001 (AZD0780 1 mg vs Placebo), p=< 0.001 (AZD0780 3 mg vs Placebo), p=< 0.001 (AZD0780 10 mg vs Placebo), p=< 0.001 (AZD0780 30 mg vs Placebo)
Laroprovstat / RosuvastatinPhase 3Small moleculePCSK9 (laroprovstat component) + HMG-CoA reductasenot yet gradedNo reviewed efficacy summary in this indication
LepodisiranPhase 3RNA / oligonucleotideLPA gene / apolipoprotein(a) mRNAPartial signal
NCT05565742: Percent Change From Baseline in Time Averaged Lipoprotein(a) [Lp(a)] Over Days 60-180 (Baseline, Days 60 - 180): 16 mg LY3819469 -39.0% ± 7.37 vs 96 mg LY3819469 -74.4% ± 2.16 vs 400 mg LY3819469 and 400 mg LY3819469 + Placebo (400 mg LY3819469 Pooled) -93.7% ± 0.38 vs Placebo 3.1% ± 8.99; p=<0.001 (16 mg LY3819469 vs Placebo), p=<0.001 (96 mg LY3819469 vs Placebo), p=<0.001 (400 mg LY3819469 and 400 mg LY3819469 + Placebo (400 mg LY3819469 Pooled) vs Placebo)
Lerodalcibep (Lerochol)Phase 3Protein / enzyme therapeuticPCSK9Reliable signal
NCT04797104: LDL-C at Week 24: placebo-adjusted reduction of 58.61% (P<.0001); co-primary endpoint, mean of Weeks 22 and 24: placebo-adjusted reduction of 65.0% (P<.0001)
NCT05004675: LDL-C change from baseline at Day 270 (mITT): -53% with lerodalcibep vs -45.3% with inclisiran (P=0.0319); per-protocol: -55.4% vs -45.4% (P=0.005)
Maridebart Cafraglutide (MariTide)Phase 3PeptideGLP-1R agonist; GIPR antagonistnot yet gradedNo reviewed efficacy summary in this indication
MDR-001
Phase 3(overall)
Small moleculeGLP-1 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
MuvalaplinPhase 3Small moleculeApolipoprotein(a) [apo(a)] kringle domain / apo(a)-apoB100 interactionPartial signal
NCT05563246: Percent Change From Baseline in Lp(a) - Assessed Via Intact Lp(a) Assay (Baseline, Week 12): 10 mg LY3473329 -47.35% ± 4.811 vs 60 mg LY3473329 -81.57% ± 1.230 vs 240 mg LY3473329 -85.71% ± 0.927 vs Placebo 0.48% ± 6.382; p=<.001 (10 mg LY3473329 vs Placebo), p=<.001 (60 mg LY3473329 vs Placebo), p=<.001 (240 mg LY3473329 vs Placebo)
NL003Phase 3Gene therapy / editingHepatocyte growth factor (HGF)not yet gradedNo reviewed efficacy summary in this indication
ObicetrapibPhase 3Small moleculeCETPPartial signal
NCT05142722: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 84 [PUC] (84 Days): Obicetrapib 10mg -29.94% (Standard Error 1.104) vs Placebo 2.7% (Standard Error 1.571)
NCT05425745: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 84 [PUC] (84 Days): Obicetrapib 10 mg -36.05% (Standard Error 1.769) vs Placebo 0.25% (Standard Error 2.48)
Obicetrapib / Ezetimibe (Evlarco)Phase 3Small moleculeCETP, NPC1L1Partial signal
NCT06005597: Effect of Fixed-Dose Combination (FDC) Compared to Placebo on LDL-C (84 Days): Fixed Dose Combination -45.58% (Standard Error 3.465) vs Placebo 3.03% (Standard Error 3.564)
OlpasiranPhase 3RNA / oligonucleotideLPA gene / apolipoprotein(a) mRNAPartial signal
NCT04270760: Percentage Change From Baseline in Lipoprotein(a) (Lp[a]) at Week 36 (Baseline and Week 36): Group 1: Olpasiran 10 mg Q12W -66.91% ± 1.78 vs Group 2: Olpasiran 75 mg Q12W -93.78% ± 1.78 vs Group 3: Olpasiran 225 mg Q12W -97.53% ± 1.82 vs Group 4: Olpasiran 225 mg Q24W -96.89% ± 1.85 vs Group 5: Placebo Q12W 3.60% ± 1.89; p=<0.001 (Group 1: Olpasiran 10 mg Q12W vs Group 5: Placebo Q12W), p=<0.001 (Group 2: Olpasiran 75 mg Q12W vs Group 5: Placebo Q12W), p=<0.001 (Group 3: Olpasiran 225 mg Q12W vs Group 5: Placebo Q12W), p=< 0.001 (Group 4: Olpasiran 225 mg Q24W vs Group 5: Placebo Q12W)
Ongericimab (Junshida)Phase 3Monoclonal antibodyPCSK9Reliable signal
NCT05325203: Percent change in LDL-C from baseline to week 24 (JS002-005/NCT05325203, HeFH, 135 patients): ongericimab 150mg Q2W -69.4% vs placebo (p<0.0001); ongericimab 450mg Q4W -80.6% vs placebo (p<0.0001)
NCT04781114: LDL-C percentage change from baseline to week 24 vs placebo: 150 mg Q2W -67.7% (95% CI -72.5% to -63.0%; P<0.0001); 300 mg Q4W -61.2% (95% CI -67.1% to -55.2%; P<0.0001).
Orforglipron (Foundayo)Phase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
PelacarsenPhase 3RNA / oligonucleotideApolipoprotein(a) mRNAPartial signal
NCT05305664: Rate of Lipoprotein Apheresis Sessions Performed Over 52 Weeks Normalized to the Weekly Lipoprotein Apheresis Schedule (Up to Week 52): Pelacarsen (TQJ230) 0.16 Apheresis sessions received per week (IQR 0.04 to 0.25) vs Placebo 0.93 Apheresis sessions received per week (IQR 0.9 to 1)
Pemafibrate (Parmodia)Phase 3Small moleculePPAR-alphaPartial signalNo reviewed efficacy summary in this indication
PMR (cilostazol ER)Phase 3Small moleculePhosphodiesterase 3 (PDE3)Weak signalNo reviewed efficacy summary in this indication
PravafenixPhase 3Small moleculeHMG-CoA reductase / PPAR-alphaPartial signalNo reviewed efficacy summary in this indication
QLC7401Phase 3RNA / oligonucleotidePCSK9not yet gradedNo reviewed efficacy summary in this indication
RanolazinePhase 3Small moleculeCardiac late sodium current (late INa, Nav1.5)Partial signal
NCT00099788: The primary end point occurred in 696 patients (21.8%) in the ranolazine group and 753 patients (23.5%) in the placebo group (hazard ratio 0.92). missed
NCT01562041: Change From Baseline in Maximum ST Segment Change Adjusted for Heart Rate (ST-HR) Index (Baseline up to Day 15): Ranolazine 500 mg — Test 1: 3.211 microvolts/beats per minute (microV/bpm) (Standard Deviation 1.6553); Test 2: 2.822 microvolts/beats per minute (microV/bpm) (Standard Deviation 1.0289); Test 3: 3.228 microvolts/beats per minute (microV/bpm) (Standard Deviation 1.891); Test 4: 2.502 microvolts/beats per minute (microV/bpm) (Standard Deviation 1.8884); Change From Baseline in Maximum ST/Heart Rate Index: -0.605 microvolts/beats per minute (microV/bpm) (Standard Deviation 1.0482)
RecaticimabPhase 3Monoclonal antibodyPCSK9Reliable signal
NCT04844125: Change in LDL-C from baseline at Week 12: -54.4% recaticimab vs -4.5% placebo; treatment difference -49.8 percentage points (95% CI -55.8 to -43.9), P<0.0001
NCT04849000: LDL-C reduction vs placebo at the primary endpoint timepoint: 150 mg Q4W -49.6% (95% CI 44.2-54.9%); 300 mg Q8W -52.8% (95% CI 48.3-57.2%); 450 mg Q12W -45.0% (95% CI 41.0-49.0%); P<0.0001 for all comparisons.
RetatrutidePhase 3PeptideGLP-1/GIP/glucagon receptor (triple)not yet gradedNo reviewed efficacy summary in this indication
RibupatidePhase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
SAL003Phase 3Monoclonal antibodyPCSK9Partial signalNo reviewed efficacy summary in this indication
Sarpogrelate (Anplag)Phase 3Small moleculeSerotonin 5-HT2A receptor (antagonist / inverse agonist)not yet gradedNo reviewed efficacy summary in this indication
SumecigrelPhase 3Small moleculeP2Y12 platelet receptorPartial signal
NCT03599284: Primary, inhibition of ADP-induced platelet aggregation (%IPA) at day 28: vicagrel 20/5 mg 30.19%, 24/6 mg 35.02%, 30/7.5 mg 45.61%, clopidogrel 32.55%; the paper reports these as comparable across all groups (P=0.0694) and sets no non-inferiority margin.
SYH2053Phase 3RNA / oligonucleotidePCSK9Partial signalNo reviewed efficacy summary in this indication
Tafolecimab (Sintbilo)Phase 3Monoclonal antibodyPCSK9Reliable signal
NCT04289285: LDL-C percent change from baseline to week 48, treatment difference vs placebo: -65.0% (97.5% CI: -70.2%, -59.9%) for tafolecimab 450 mg Q4W; -57.3% (97.5% CI: -64.0%, -50.7%) for 600 mg Q6W; both P < 0.0001
NCT04709536: Percent change in LDL-C from baseline to Week 12: tafolecimab -68.9% (SE 1.4%) vs placebo -5.8% (SE 1.8%); treatment difference -63.0% (95% CI -66.5% to -59.6%, P<0.0001)
ZiltivekimabPhase 3Monoclonal antibodyInterleukin-6Partial signal
NCT05021835: 3-point MACE (CV death, non-fatal MI, non-fatal stroke): HR 0.99 (95% CI 0.88-1.11) for ziltivekimab vs placebo. missed
Zovaglutide
Phase 3(overall)
PeptideGLP-1 receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
NeovasculgenPhase 2/3Gene therapy / editingVEGF165 gene therapy (angiogenic plasmid)Partial signal
NCT03068585: Pain-free walking distance increased in the pCMV-vegf165 (Neovasculgen) treatment group by 110.4% at 6 months, versus no positive results in the standard-treatment control group
ABP-745Phase 2Small moleculeNLRP3 inflammasomenot yet gradedNo reviewed efficacy summary in this indication
ACP-01Phase 2Biologic (subtype unspecified)Autologous angiogenic cell precursor (ACP) therapyPartial signal
NCT02551679: Primary composite (de-novo gangrene, doubling of wound size, major amputation or death within 1 year): 12 of 46 participants on ACP-01 vs 3 of 21 on placebo, hazard ratio 2.046 (95% CI 0.577 to 7.255), p=0.258 (CT.gov posted results). missed
APACPhase 2PeptideVascular injury site glycocalyx / coagulation cascadenot yet gradedNo reviewed efficacy summary in this indication
BW-20829Phase 2RNA / oligonucleotideLipoprotein(a) [Lp(a)] production pathwaynot yet gradedNo reviewed efficacy summary in this indication
CNIC-Ferrer Polypill (Trinomia)Phase 2Small moleculeMulti-mechanism secondary-prevention polypillPartial signalNo reviewed efficacy summary in this indication
DNV001Phase 2RNA / oligonucleotidePCSK9not yet gradedNo reviewed efficacy summary in this indication
Ecnoglutide (VRB-101)
Phase 2(overall)
PeptideGLP-1 receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
EDP167Phase 2RNA / oligonucleotideANGPTL3Weak signalNo reviewed efficacy summary in this indication
Exenatide (PT320)
Phase 2(overall)
PeptideGLP-1 receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
TE-8105
Phase 2(overall)
PeptideGLP-1 receptor
Weak signal(overall)
No reviewed efficacy summary in this indication
ZT006
Phase 2(overall)
PeptideGLP-1 receptor
Weak signal(overall)
No reviewed efficacy summary in this indication
Berberine Ursodeoxycholate (HTD1801)Phase 1/2Small moleculeAMPK pathway / NLRP3 inflammasome (dual)Weak signal
NCT03381287: Day 28, 2000 mg/day (highest dose) vs placebo: total cholesterol -8.2% (P=0.0004); LDL-C -10.4% (P=0.0006). Lower doses (500 mg, 1000 mg) did not reach significance.
BMF-650
Phase 1(overall)
Small moleculeGLP-1 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
DehydraTECH-CBD / Semaglutide
Phase 1(overall)
CombinationOral peptide delivery platform, GLP-1 receptor
Weak signal(overall)
No reviewed efficacy summary in this indication
IBI3032
Phase 1(overall)
Small moleculeGLP-1 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
Liraglutide (HUC2-676)
Phase 1(overall)
PeptideGLP-1 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
PF-08642534
Phase 1(overall)
UndisclosedGLP-1 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
PF-08656795
Phase 1(overall)
UndisclosedGLP-1 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
Semaglutide (DWRX5003)
Phase 1(overall)
PeptideGLP-1 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
MGL-2086
—(overall)
Small moleculeGLP-1 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication

Large race: only the 82 furthest-along competitors are listed; 57 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(7 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Liraglutide (Victoza) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 4Atrial FibrillationActive not recruiting
Est. primary completion 2026-12-31 · NCT03856632 · CT.gov ↗
What to watch
2027 (4)
March 2027 (1)
Phase 3Delirium, PostoperativeRecruiting
Est. primary completion 2027-03-31 · NCT06361238 · CT.gov ↗
What to watch
April 2027 (1)
Phase 4Metabolic SyndromeRecruiting
Est. primary completion 2027-04-30 · NCT04575844 · CT.gov ↗
What to watch
June 2027 (1)
Phase 4Type 2 DiabetesRecruiting
Est. primary completion 2027-06 · NCT03883412 · CT.gov ↗
What to watch
December 2027 (1)
Phase 4Type 2 DiabetesRecruiting
Est. primary completion 2027-12-31 · NCT07244003 · CT.gov ↗
What to watch
2028 (2)
April 2028 (1)
Phase 4Healthy, Growth Hormone DeficiencyRecruiting
Est. primary completion 2028-04-30 · NCT05681299 · CT.gov ↗
What to watch
October 2028 (1)
Phase 2Type 2 DiabetesRecruiting
Est. primary completion 2028-10-30 · NCT06976619 · CT.gov ↗
What to watch

See the full readout calendar ↗